CN104998174A - 一种防治脑萎缩的益智健脑制剂及制法 - Google Patents
一种防治脑萎缩的益智健脑制剂及制法 Download PDFInfo
- Publication number
- CN104998174A CN104998174A CN201510503756.2A CN201510503756A CN104998174A CN 104998174 A CN104998174 A CN 104998174A CN 201510503756 A CN201510503756 A CN 201510503756A CN 104998174 A CN104998174 A CN 104998174A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- herba
- brain
- subsequent use
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 46
- 238000005728 strengthening Methods 0.000 title abstract description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 29
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 29
- 235000008434 ginseng Nutrition 0.000 claims abstract description 29
- 241001165877 Dioscorea subcalva Species 0.000 claims abstract description 23
- 235000002190 Dioscorea subcalva Nutrition 0.000 claims abstract description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 69
- 239000000843 powder Substances 0.000 claims description 67
- 239000003814 drug Substances 0.000 claims description 60
- 208000024806 Brain atrophy Diseases 0.000 claims description 59
- 210000004556 brain Anatomy 0.000 claims description 45
- 241000003857 Parmelia saxatilis Species 0.000 claims description 32
- 241000208340 Araliaceae Species 0.000 claims description 29
- 241000255791 Bombyx Species 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 241000628997 Flos Species 0.000 claims description 24
- 241000207783 Ipomoea Species 0.000 claims description 24
- 241001602951 Hypoleucis Species 0.000 claims description 23
- 235000021506 Ipomoea Nutrition 0.000 claims description 23
- 239000000706 filtrate Substances 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 19
- 230000003203 everyday effect Effects 0.000 claims description 17
- 239000006187 pill Substances 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 15
- 239000012467 final product Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 206010013786 Dry skin Diseases 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 238000005325 percolation Methods 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- -1 filters Substances 0.000 claims description 5
- 239000011812 mixed powder Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 229920002261 Corn starch Polymers 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003610 charcoal Substances 0.000 claims description 4
- 239000008120 corn starch Substances 0.000 claims description 4
- 239000002274 desiccant Substances 0.000 claims description 4
- 238000007654 immersion Methods 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000004570 mortar (masonry) Substances 0.000 claims description 3
- 238000000643 oven drying Methods 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 235000013399 edible fruits Nutrition 0.000 abstract description 7
- 230000002490 cerebral effect Effects 0.000 abstract description 6
- 241000255789 Bombyx mori Species 0.000 abstract description 3
- 235000007516 Chrysanthemum Nutrition 0.000 abstract description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract description 2
- 241001080798 Polygala tenuifolia Species 0.000 abstract description 2
- 244000042324 Trifolium repens Species 0.000 abstract description 2
- 210000004958 brain cell Anatomy 0.000 abstract description 2
- 230000003833 cell viability Effects 0.000 abstract description 2
- 230000019522 cellular metabolic process Effects 0.000 abstract description 2
- 235000015763 Artemisia ludoviciana Nutrition 0.000 abstract 1
- 241000244099 Corallodiscus Species 0.000 abstract 1
- 241000933771 Ficus erecta Species 0.000 abstract 1
- 241000608847 Gnaphalium Species 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 241001275983 Merremia hungaiensis Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000010394 Solidago odora Nutrition 0.000 abstract 1
- 240000004802 Stachys palustris Species 0.000 abstract 1
- 235000010729 Trifolium repens Nutrition 0.000 abstract 1
- 244000126002 Ziziphus vulgaris Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 235000005285 woundwort Nutrition 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 description 18
- 210000003734 kidney Anatomy 0.000 description 17
- 230000006870 function Effects 0.000 description 15
- 239000000796 flavoring agent Substances 0.000 description 13
- 235000019634 flavors Nutrition 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 8
- 231100000614 poison Toxicity 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 208000002173 dizziness Diseases 0.000 description 6
- 206010044565 Tremor Diseases 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 5
- 229930182470 glycoside Natural products 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000002591 computed tomography Methods 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 150000004702 methyl esters Chemical class 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 206010006100 Bradykinesia Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 208000006083 Hypokinesia Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 208000000729 Schizencephaly Diseases 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000005021 gait Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- VGTALXLMFZXQSK-SORNOFNASA-N (2s,3r,4s,6ar,6br,8as,12as,14br)-2,3-dihydroxy-6b-(hydroxymethyl)-4,6a,11,11,14b-pentamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylic acid Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)C2CC[C@@]3(C)[C@]4(CO)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CCC3[C@]21C VGTALXLMFZXQSK-SORNOFNASA-N 0.000 description 2
- RIXNFYQZWDGQAE-DFHVBEEKSA-N (4as,6ar,6as,6br,8ar,10s,12ar,14bs)-10-acetyloxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C([C@H]1C2=CC[C@H]34)C(C)(C)CC[C@]1(C(O)=O)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)C)C1(C)C RIXNFYQZWDGQAE-DFHVBEEKSA-N 0.000 description 2
- PHFUCJXOLZAQNH-OTMOLZNZSA-N Acetylursolic acid Chemical compound C1C[C@H](OC(C)=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PHFUCJXOLZAQNH-OTMOLZNZSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- YLOYKYXNDHOHHT-UHFFFAOYSA-N Atranorin Chemical compound CC1=C(O)C(C(=O)OC)=C(C)C=C1OC(=O)C1=C(C)C=C(O)C(C=O)=C1O YLOYKYXNDHOHHT-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- VGTALXLMFZXQSK-UHFFFAOYSA-N Presenegenin Natural products C1C(O)C(O)C(C)(C(O)=O)C2CCC3(C)C4(CO)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C VGTALXLMFZXQSK-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229930187719 Soyasaponin Natural products 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000037006 agalactosis Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 235000008384 feverfew Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- QQTKVXCQLZIJPP-UHFFFAOYSA-N salazinic acid Chemical compound O1C2=C3C(O)OC(=O)C3=C(O)C(CO)=C2OC(=O)C2=C1C(C=O)=C(O)C=C2C QQTKVXCQLZIJPP-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- FKKZBCYPCGDQKZ-UHFFFAOYSA-N tenuifolin Natural products CC1(C)CCC2(CCC3(O)C(=CCC4C5(C)CC(O)C(OC6OC(CO)C(O)C(O)C6O)C(C)(C5CCC34C)C(=O)O)C2C1)C(=O)O FKKZBCYPCGDQKZ-UHFFFAOYSA-N 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- OGJKMZVUJJYWKO-CYBMUJFWSA-N (+)-Stepharine Natural products C([C@H]1NCCC=2C=C(C(=C3C=21)OC)OC)C13C=CC(=O)C=C1 OGJKMZVUJJYWKO-CYBMUJFWSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- KXPKWHNZKVLCRR-UHFFFAOYSA-N 6-aminopyrimidine-4-carboxylic acid Chemical compound NC1=CC(C(O)=O)=NC=N1 KXPKWHNZKVLCRR-UHFFFAOYSA-N 0.000 description 1
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 201000002882 Agraphia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010062542 Arterial insufficiency Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000296615 Celastrus strigillosus Species 0.000 description 1
- 206010008027 Cerebellar atrophy Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008096 Cerebral atrophy Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- CBJRVPYJFXDQDY-UHFFFAOYSA-N Cloversaponin I Chemical compound OCC1(C)C2CCC3(C)C4(C)CCC5(C)C(=O)CC(C)(C)CC5C4=CCC3C2(C)CCC1OC1OC(C(O)=O)C(O)C(O)C1O CBJRVPYJFXDQDY-UHFFFAOYSA-N 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241000234272 Dioscoreaceae Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010014357 Electric shock Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 241000146384 Glaux Species 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010064950 Head titubation Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- CJJVPWAZSXVOOK-IGTKYRGASA-N Jujuboside B Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@@H](O)CO[C@H]1O[C@@H]1C(C)(C)[C@H](CC[C@@]2(C)[C@@]34C[C@]5([C@H]([C@@](C[C@@H](O5)C=C)(C)O)[C@H]4CC[C@H]42)OC3)[C@]4(C)CC1 CJJVPWAZSXVOOK-IGTKYRGASA-N 0.000 description 1
- OAVAUZCEOWCYCC-BYHRGCEUSA-N Jujuboside B Natural products C[C@@H]1O[C@@H](O[C@H]2[C@H](O[C@H]3CC[C@@]4(C)[C@@H](CC[C@]5(C)[C@@H]4CC[C@@H]6[C@H]7[C@](C)(O)C[C@@H](O[C@@]78C[C@@]56CO8)C=C(C)C)C3(C)C)OC[C@H](O)[C@@H]2O[C@@H]9O[C@H](CO)[C@@H](O)[C@H](O)[C@H]9O[C@@H]%10OC[C@@H](O)[C@H](O)[C@H]%10O)[C@H](O)[C@H](O)[C@H]1O OAVAUZCEOWCYCC-BYHRGCEUSA-N 0.000 description 1
- URRZRRQMNMZIAP-UHFFFAOYSA-N Kudzusapogenol C Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)C(O)CC3(C)CCC21C URRZRRQMNMZIAP-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000735234 Ligustrum Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000349681 Parathelypteris glanduligera Species 0.000 description 1
- 241001310330 Parmeliaceae Species 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- QMQIQBOGXYYATH-IDABPMKMSA-N Ruscogenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)[C@H](O)C[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 QMQIQBOGXYYATH-IDABPMKMSA-N 0.000 description 1
- BSUPFYRQXCQGLJ-UHFFFAOYSA-N Ruscogenin Natural products CC1CCC2(OC1)OC3C(O)C4C5CC=C6CC(O)CC(O)C6(C)C5CCC4(C)C3C2C BSUPFYRQXCQGLJ-UHFFFAOYSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 241000522620 Scorpio Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 208000003028 Stuttering Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241001646982 Thamnolia vermicularis Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 241000244317 Tillandsia usneoides Species 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- PHFUCJXOLZAQNH-UHFFFAOYSA-N Ursolic acid acetat Natural products C1CC(OC(C)=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(C)C5C4=CCC3C21C PHFUCJXOLZAQNH-UHFFFAOYSA-N 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- OAVAUZCEOWCYCC-NZTCAOINSA-N Zizyphussaponin III Natural products C[C@@H]1O[C@@H](O[C@H]2[C@H](O[C@H]3CC[C@@]4(C)[C@@H](CC[C@]5(C)[C@@H]4CC[C@@H]6[C@H]7[C@](C)(O)C[C@@H](O[C@@]78C[C@@]56CO8)C=C(C)C)C3(C)C)OC[C@H](O)[C@@H]2O[C@@H]9O[C@H](CO)[C@@H](O)[C@H](O)[C@H]9O[C@@H]%10OC[C@@H](O)[C@H](O)[C@H]%10O)[C@H](O)[C@H](O)[C@@H]1O OAVAUZCEOWCYCC-NZTCAOINSA-N 0.000 description 1
- OGJKMZVUJJYWKO-ZDUSSCGKSA-N ac1lh1t2 Chemical compound C([C@@H]1NCCC=2C=C(C(=C3C=21)OC)OC)C13C=CC(=O)C=C1 OGJKMZVUJJYWKO-ZDUSSCGKSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- QLTCHMYAEJEXBT-UHFFFAOYSA-N alpha-beta-D-glucopyranosyloxy-isobutyronitrile Natural products N#CC(C)(C)OC1OC(CO)C(O)C(O)C1O QLTCHMYAEJEXBT-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000009670 cang er zi wan Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 206010058319 dysgraphia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- QMQIQBOGXYYATH-UHFFFAOYSA-N epiruscogenin Natural products CC1C(C2(CCC3C4(C)C(O)CC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 QMQIQBOGXYYATH-UHFFFAOYSA-N 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000001951 hemoperfusion Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000003248 hydroxytyrosol Nutrition 0.000 description 1
- 229940095066 hydroxytyrosol Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- QLTCHMYAEJEXBT-ZEBDFXRSSA-N linamarin Chemical compound N#CC(C)(C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QLTCHMYAEJEXBT-ZEBDFXRSSA-N 0.000 description 1
- CRTWQTRFSBJGLK-UHFFFAOYSA-N linamarin Natural products CC(C)(C#N)C1OC(CO)C(O)C(O)C1O CRTWQTRFSBJGLK-UHFFFAOYSA-N 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- STKUCSFEBXPTAY-YTECAPLWSA-N methyl (5e,6s)-5-ethylidene-4-[2-oxo-2-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[2-(4-hydroxyphenyl)ethoxy]oxan-2-yl]methoxy]ethyl]-6-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4h-pyran-3-carboxylate Chemical compound O([C@@H]\1OC=C(C(C/1=C\C)CC(=O)OC[C@@H]1[C@H]([C@H](O)[C@@H](O)[C@H](OCCC=2C=CC(O)=CC=2)O1)O)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O STKUCSFEBXPTAY-YTECAPLWSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- STKUCSFEBXPTAY-KCWGXYKVSA-N nuezhenoside Natural products COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=CC)[C@@H]1CC(=O)OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O STKUCSFEBXPTAY-KCWGXYKVSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- IUCHKMAZAWJNBJ-RCYXVVTDSA-N oleanolic acid 3-O-beta-D-glucosiduronic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O IUCHKMAZAWJNBJ-RCYXVVTDSA-N 0.000 description 1
- 235000011576 oleuropein Nutrition 0.000 description 1
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
- IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 description 1
- 229960001227 oxiracetam Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229930182487 phenolic glycoside Natural products 0.000 description 1
- 150000007950 phenolic glycosides Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- OGJKMZVUJJYWKO-UHFFFAOYSA-N proaporphine Natural products C1=2C3=C(OC)C(OC)=CC=2CCNC1CC13C=CC(=O)C=C1 OGJKMZVUJJYWKO-UHFFFAOYSA-N 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229940109990 ruscogenin Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000009490 scorpio Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- MADZMXIFUWFDJK-AEARDBQCSA-N soyasapogenol B Natural products CC1(C)C[C@@H](O)[C@]2(C)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O[C@@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)C(=O)O)[C@](C)(CO)[C@@H]5CC[C@@]34C)[C@H]2C1 MADZMXIFUWFDJK-AEARDBQCSA-N 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种防治脑萎缩的益智健脑制剂,由下列原料药制备而成,均为重量份:人参10-15;山土瓜7-12;三消草9-13;水苏6-14;远志8-15;石花7-10;益智仁9-15;大枣11-18;牛奶浆根8-14;菊花10-16;牛尾参7-16;天水蚁草9-14;白僵蚕6-10;女贞子10-13。本发明的优良效果还表现在:本发明药物不仅具有活血化瘀、健脑通窍、益智安神的作用,还能有效促进脑细胞代谢,提高大脑中枢细胞活力,显著改善脑萎缩症状。
Description
技术领域
本发明涉及中医中药领域,特别是涉及一种防治脑萎缩的益智健脑制剂及制备方法。
背景技术
脑萎缩是一种慢性精神衰退性疾病。临床以记忆力障碍,情感障碍,性格行为的改变,智能减退为主要特征。小脑、橄榄体、桥脑萎缩是一种以共济失调为主的慢性进行性疾病。临床以步态不稳,书写障碍,肢体震颤,言语含糊,骨骼畸形为主要特征。中医称为足能伸而走不稳,手能举而抓不稳,步态蹒跚,动作笨拙,言语謇涩,或有头摇、颤震、痉挛。本病多发于50岁以上的患者,病程可逾数年甚至10余年,女性多于男性。可分为脑动脉硬化性脑萎缩、老年痴呆性脑萎缩、中风后脑萎缩、颈椎病及脑外伤后导致脑动脉供血不足性脑萎缩、小儿窒息后缺氧性脑萎缩等。本病最主要的致病因素是脑血管长期慢性缺血造成的。红细胞变形能力下降,则微血管的有效血液灌注不足,脑组织处于慢性缺血、缺氧状态,脑细胞形态及功能受到影响,即形成脑萎缩。本病的病变可见脑回变平,脑沟增宽,脑室脑池扩大,脑重量减轻。多见大脑皮质萎缩,因部位和涉及范围不同又可分为局限性和弥漫性脑萎缩。
脑萎缩的临床表现分为大脑机能衰退和痴呆等智能减退两大类,主要与脑萎缩发生的部位及程度有关。脑萎缩的症状,弥漫性大脑皮层萎缩以痴呆、智能减退、记忆障碍、性格改变、行为障碍为主。有的伴有偏瘫和癫痫发作。局灶性脑萎缩以性格行为改变为主;小脑萎缩以语言障碍、肢体共济失调和意向性震颤为主。根据其临床表现可纳入中医学痴呆、健忘、眩晕、震颤、失眠、癫证、郁证、痿证、虚损等病证范畴。中医认为本病虽病位在脑,但与各脏腑功能密切相关,病理机制属本虚标实。临床上可将脑萎缩分为五型辨治。肾精不足,髓海空虚型:主要表现为头晕耳鸣,神疲倦怠、腰膝酸软,毛发焦枯,舌淡苔白,脉虚无力或沉细。治宜滋补肝肾,填精健脑。
申请公布号CN102908570A(申请号201210373064.7)的中国发明专利文献公开了一种治疗脑萎缩的中药,各原料组分的重量配比为:白毛蛇8-12、积雪草1-5、石菖蒲4-8、川芎8-12、胡芦巴6-10、枸杞13-17、丹参8-12、白苏叶1-5、南蛇藤果13-17、制首乌4-8、益智仁13-17、西藏雪茶4-8。申请公布号CN101983711A(申请号201010503644.4)的中国发明专利文献公开了一种治疗脑萎缩的中药,由以下重量配比的原料组成:白芷10克;黄芩10克;升麻10克;苍耳子10克;辛夷10克;天麻10克;郁金10克;石菖蒲10克;制南星10克;桔梗10克;红茶10克。申请公布号CN102631436A(申请号201210142857.8)的中国发明专利文献公开了一种治疗脑萎缩的药剂,由下列原料药按重量份计制成:黄芪20-50份、当归10-30份、红花5-20份、木瓜10-30份、苍术10-40份、白芷10-40份、五加皮10-30份、荆芥10-30份、防风10-30份、川芎10-30份、羌活5-20份、伸筋草10-30份和透骨草10-30份。
近年来,国内外对脑萎缩病的研究有了飞速的发展,在防治和诊断上取得新进展,治疗脑萎缩的药物也不断增多。虽然这些药物有不同程度的疗效,但大多只能起到缓解当时症状、维持原状的作用,治标而不治本,尤其西方医学目前还没有更好的办法。现有的治疗脑萎缩的中药药物大多见效慢、疗效差、服药时间长、治疗面单一,与该病相关的体症不能兼顾治疗。
发明内容
针对现有技术的不足,本发明的目的是提供一种制备简单、服用方便、安全有效的防治脑萎缩的益智健脑制剂及制法。本发明益智健脑制剂疗效确切便于临床使用。
本发明的技术方案是:
一种防治脑萎缩的益智健脑制剂,由下列原料药制备而成,均为重量份:人参10-15;山土瓜7-12;三消草9-13;水苏6-14;远志8-15;石花7-10;益智仁9-15;大枣11-18;牛奶浆根8-14;菊花10-16;牛尾参7-16;天水蚁草9-14;白僵蚕6-10;女贞子10-13。
优选的方案中,人参11.5-13.5;山土瓜9-10;三消草10-12;水苏8-12;远志10-13;石花8-9;益智仁11-13;大枣13-16;牛奶浆根10-12;菊花12-14;牛尾参10-13;天水蚁草10.5-12.5;白僵蚕7-9;女贞子11-12。
更加优选的,人参12.5;山土瓜9.5;三消草11;水苏10;远志11.5;石花8.5;益智仁12;大枣14.5;牛奶浆根11;菊花13;牛尾参11.5;天水蚁草11.5;白僵蚕8;女贞子11.5。
一种防治脑萎缩的益智健脑制剂,将其制成药学上可接受的丸剂,制备方法如下:
(1)取石花于黄酒中浸泡12-18分钟(优选浸泡15分钟),取出,文火加热炒干,研末,备用;白僵蚕置于瓦片上,炭火略炒至微黄色,取出放凉,研末备用;
(2)取人参切薄片和大枣一同置于药锅中,加冷水浸泡50-70分钟(优选加冷水浸泡60分钟),然后盖盖,大火加热煮沸,转小火煎煮28-46分钟(优选转小火煎煮37分钟),过滤,滤液继续文火慢煎至原体积的1/4,放凉备用;
(3)将益智仁、女贞子和远志混合,粉碎成细粉,置于密闭容器中,加3.5-6.5倍量的乙醇于室温下浸泡3-5天(优选加5.0倍量的乙醇于室温下浸泡4天),期间每天搅拌,待浸泡结束后,经三层面纱布过滤,滤液回收乙醇,减压浓缩至65℃相对密度为1.18-1.22的清膏,真空干燥,得干膏粉,备用;
(4)将山土瓜、三消草、水苏、牛奶浆根、菊花、牛尾参和天水蚁草置于中药干燥剂机中充分干燥,然后置于粉碎机中粉碎成细粉,备用;
(5)将步骤(1)、(3)和(4)处理后的原料药粉混合,过115-145目筛(优选过130目筛),加入到步骤(2)所得药液中,加入其它辅料,机械搅拌,混合均匀,加工成梧桐子大小的丸剂,即得。
上述一种防治脑萎缩的益智健脑丸剂的制备方法,优选的方案是,步骤(1)中石花与黄酒的质量比为1:0.15-0.25(优选的石花与黄酒的质量比为1:0.18-0.22,更加优选的石花与黄酒的质量比为1:0.20)。
上述一种防治脑萎缩的益智健脑丸剂的制备方法,优选的方案是,步骤(3)中每天搅拌1-5次(优选的每天搅拌2-4次,更加优选的每天搅拌3次)。
上述一种防治脑萎缩的益智健脑丸剂的制备方法,优选的方案是,步骤(5)中所述辅料为质量分数为9%的糖细粉和质量分数为3.5%的玉米淀粉。
所述胶囊剂的制备方法是:
(1)取益智仁、女贞子、白僵蚕、菊花和石花置于密闭容器中,加22%-40%的姜汁拌匀(优选加30%的姜汁拌匀),闷8-14分钟(优选闷11分钟),取出,文火加热炒干,置于研钵中,研成细粉,备用;
(2)取三消草、水苏、大枣和天水蚁草置于药锅中,加清水没过药面,文火加热煎煮两次,第一次煎煮18-30分钟(优选第一次煎煮24分钟),第二次煎煮10-20分钟(优选第二次煎煮15分钟),合并两次煎液,过滤,滤液减压浓缩成稠膏,备用;
(3)取人参切成薄片,同山土瓜、远志、牛奶浆根和牛尾参一同粉碎成细粉,置于中药提取器中,以5-7倍量的55%的乙醇为溶剂(优选以6倍量的55%的乙醇为溶剂),加热回流提取24-40分钟(优选加热回流提取32分钟),收集提取液,过滤,回收乙醇,减压浓缩至60℃相对密度为1.22-1.25的稠膏,备用;
(4)将步骤(2)和(3)所得稠膏混合,加入步骤(1)所得药粉,搅拌使混合均匀,干燥,制粒,整粒,过六号筛,装入胶囊壳,即得。
所述汤剂的制备方法是:
(1)取益智仁、白僵蚕、女贞子、远志和牛奶浆根于48-62℃干燥1-2小时(优选于55℃干燥1.5小时),趁热粉碎成细粉,将混合细粉平铺于渗漉筒内,以60%-80%的乙醇为溶剂(优选以70%的乙醇为溶剂),按照渗漉法收集渗漉液,待渗漉液的量为混合药粉量的16-20倍(优选渗漉液的量为混合药粉量的18倍)时,停止渗漉,过滤,回收乙醇,减压浓缩成稠膏,喷雾干燥得干膏粉,放凉,研细,备用;
(2)取人参切薄片,加清水文火慢煎1-2小时(优选加清水文火慢煎1.5小时),过滤,滤液备用;
(3)取山土瓜、三消草、水苏、石花、大枣、菊花、牛尾参和天水蚁草置于砂锅内,加4-7倍量的清水浸泡2-4小时(优选加5.5倍量的清水浸泡3小时),然后大火加热煮沸3-7分钟(优选大火加热煮沸5分钟),转小火煎煮45-65分钟(优选小火煎煮55分钟),过滤,滤液备用;
(4)将步骤(2)和步骤(3)所得滤液混合,减压浓缩至原体积的1/3,然后加入步骤(1)处理后的干膏粉,搅拌均匀,灭菌封装,即得。
所述片剂的制备方法是:
(1)取人参切薄片,大枣去核、切薄片,一同置于干燥机中,低温烘干,研磨成细粉,备用;
(2)将益智仁、女贞子置于15%的黄酒中,拌匀,闷10-20分钟(优选闷15分钟),取出,置于炒至容器中,与白僵蚕一同翻炒至微黄色,取出放凉,研成细粉,备用;
(3)将除步骤(1)和(2)以外的原料药置于热风干燥机中,于72-80℃干燥34-50分钟(优选于76℃干燥42分钟),再于45-55℃干燥1-2小时(优选于50℃干燥1.5小时),取出,置于粉碎机中粉碎成细粉,备用;
(4)将步骤(1)-(3)处理后的原料药粉混合,加入糊精细粉和硬脂酸镁,搅拌均匀,过65-95目筛(优选过80目筛),置于压片机中压成片剂,即得。
本发明组方科学,制备方法简单,使用方便、效果显著。除此之外,本发明的优良效果还表现在:
1、本发明运用中医理论分析处方组成,根据各药味所含成分的理化性质与药理作用的研究结果,研究得到了合理、稳定的活性成分的制备方法;
2、本发明药物不仅具有活血化瘀、健脑通窍、益智安神的作用,还能有效促进脑细胞代谢,提高大脑中枢细胞活力,显著改善脑萎缩症状;
3、本发明药物是在传统的中医辨证治疗的基础上结合现代最新科研成果研制而成的,诸药合用,具有疗效显著、安全方便、价格低廉的特点。
具体实施方式
下面结合实施例和实验例详细说明本发明的技术方案,但保护范围不限于此。
实施例1 一种防治脑萎缩的益智健脑制剂,由下列原料药制备而成,均为重量份(50g/份):人参10份;山土瓜7份;三消草9份;水苏6份;远志8份;石花7份;益智仁9份;大枣11份;牛奶浆根8份;菊花10份;牛尾参7份;天水蚁草9份;白僵蚕6份;女贞子10份。
一种防治脑萎缩的益智健脑的丸剂的制备方法是:
(1)取石花于黄酒中(石花与黄酒的质量比为1:0.15)浸泡12分钟,取出,文火加热炒干,研末,备用;白僵蚕置于瓦片上,炭火略炒至微黄色,取出放凉,研末备用;
(2)取人参切薄片和大枣一同置于药锅中,加冷水浸泡50分钟,然后盖盖,大火加热煮沸,转小火煎煮28分钟,过滤,滤液继续文火慢煎至原体积的1/4,放凉备用;
(3)将益智仁、女贞子和远志混合,粉碎成细粉,置于密闭容器中,加3.5倍量的乙醇于室温下浸泡3天,期间每天搅拌1次,待浸泡结束后,经三层面纱布过滤,滤液回收乙醇,减压浓缩至65℃相对密度为1.20的清膏,真空干燥,得干膏粉,备用;
(4)将山土瓜、三消草、水苏、牛奶浆根、菊花、牛尾参和天水蚁草置于中药干燥剂机中充分干燥,然后置于粉碎机中粉碎成细粉,备用;
(5)将步骤(1)、(3)和(4)处理后的原料药粉混合,过115目筛,加入到步骤(2)所得药液中,加入其它辅料(辅料为质量分数为9%的糖细粉和质量分数为3.5%的玉米淀粉),机械搅拌,混合均匀,加工成梧桐子大小的丸剂,即得。
本发明所得丸剂的的服用方法是:每天三次,每次8-12粒,温水送服,30天一个疗程。
典型病例:赵XX,男,56岁,滨州人。患者自述三年前无明显诱因出现脑缺血症状,被家人紧急送往当地人民医院进行救治,后康复出院。随后出现步态不稳、反应迟钝等症状,有时外出会忘记回家的路,家人甚为担心。四处求医问药,希望患者能早日康复。后经朋友介绍于2012年5月2日来我院检查治疗。检查:患者面色晦暗无华、步态不稳、形寒怕冷,记忆力和计算能力减退,反应迟钝,舌淡、少苔、脉沉数。经脑部CT提示:脑沟、脑裂扩大,额回变窄,诊断为脑萎缩。
服用本实施例所得一种防治脑萎缩的益智健脑的丸剂,服用方法:每天三次,每次8-12粒,温水送服,30天一个疗程。治疗两个疗程后,患者症状明显好转,行走基本恢复正常,其他症状得到控制,继续用药两个疗程,患者的各种不良症状消失,记忆力恢复正常,睡眠质量提高,思维清晰。一年后回访,患者身体健康,无复发。
实施例2 一种防治脑萎缩的益智健脑制剂,由下列原料药制备而成,均为重量份(30g/份):人参15份;山土瓜12份;三消草13份;水苏14份;远志15份;石花10份;益智仁15份;大枣18份;牛奶浆根14份;菊花16份;牛尾参16份;天水蚁草14份;白僵蚕10份;女贞子13份。
一种防治脑萎缩的益智健脑胶囊剂的制备方法是:
(1)取益智仁、女贞子、白僵蚕、菊花和石花置于密闭容器中,加30%的姜汁拌匀,闷11分钟,取出,文火加热炒干,置于研钵中,研成细粉,备用;
(2)取三消草、水苏、大枣和天水蚁草置于药锅中,加清水没过药面,文火加热煎煮两次,第一次煎煮24分钟,第二次煎煮15分钟,合并两次煎液,过滤,滤液减压浓缩成稠膏,备用;
(3)取人参切成薄片,同山土瓜、远志、牛奶浆根和牛尾参一同粉碎成细粉,置于中药提取器中,以6倍量的55%的乙醇为溶剂,加热回流提取32分钟,收集提取液,过滤,回收乙醇,减压浓缩至60℃相对密度为1.23的稠膏,备用;
(4)将步骤(2)和(3)所得稠膏混合,加入步骤(1)所得药粉,搅拌使混合均匀,干燥,制粒,整粒,过六号筛,装入胶囊壳,即得。
本发明所得胶囊剂的服用方法是:每天三次,每次4-5粒,温水送服,30天一个疗程。
实施例3 一种防治脑萎缩的益智健脑制剂,由下列原料药制备而成,均为重量份(45g/份):人参11.5份;山土瓜9份;三消草10份;水苏8份;远志10份;石花8份;益智仁11份;大枣13份;牛奶浆根10份;菊花12份;牛尾参10份;天水蚁草10.5份;白僵蚕7份;女贞子11份。
一种防治脑萎缩的益智健脑汤剂的制备方法是:
(1)取益智仁、白僵蚕、女贞子、远志和牛奶浆根于55℃干燥1.5小时,趁热粉碎成细粉,将混合细粉平铺于渗漉筒内,以70%的乙醇为溶剂,按照渗漉法收集渗漉液,待渗漉液的量为混合药粉量的18倍时,停止渗漉,过滤,回收乙醇,减压浓缩成稠膏,喷雾干燥得干膏粉,放凉,研细,备用;
(2)取人参切薄片,加清水文火慢煎1.5小时,过滤,滤液备用;
(3)取山土瓜、三消草、水苏、石花、大枣、菊花、牛尾参和天水蚁草置于砂锅内,加5.5倍量的清水浸泡3小时,然后大火加热煮沸5分钟,转小火煎煮55分钟,过滤,滤液备用;
(4)将步骤(2)和步骤(3)所得滤液混合,减压浓缩至原体积的1/3,然后加入步骤(1)处理后的干膏粉,搅拌均匀,灭菌封装,即得。
本发明所得汤剂的服用方法是:每天两次,每次120-150mL,温热服用,30天一个疗程。
实施例4 一种防治脑萎缩的益智健脑制剂,由下列原料药制备而成,均为重量份(35g/份):人参13.5份;山土瓜10份;三消草12份;水苏12份;远志13份;石花9份;益智仁13份;大枣16份;牛奶浆根12份;菊花14份;牛尾参13份;天水蚁草12.5份;白僵蚕9份;女贞子12份。
一种防治脑萎缩的益智健脑片剂的制备方法是:
(1)取人参切薄片,大枣去核、切薄片,一同置于干燥机中,低温烘干,研磨成细粉,备用;
(2)将益智仁、女贞子置于15%的黄酒中,拌匀,闷15分钟,取出,置于炒至容器中,与白僵蚕一同翻炒至微黄色,取出放凉,研成细粉,备用;
(3)将除步骤(1)和(2)以外的原料药置于热风干燥机中,于76℃干燥42分钟,再于50℃干燥1.5小时,取出,置于粉碎机中粉碎成细粉,备用;
(4)将步骤(1)-(3)处理后的原料药粉混合,加入糊精细粉和硬脂酸镁,搅拌均匀,过80目筛,置于压片机中压成片剂,即得。
本发明所得片剂的服用方法是:每天三次,每次4-6片,温水送服,30天一个疗程。
典型病例:魏XX,女,63岁,临沂人。患者2009年7月无明显诱因出现行走不稳,走路摇晃,说话不流利、表达不清楚,在某中医院检查诊断为脑萎缩,给予输液及中药内服治疗,治疗两个多月,患者症状未见明显好转,记忆力大幅下降,不爱说话,食欲减退,身形一天天消瘦,家人看在眼里急在心上,四处寻医问药,后经人介绍,抱着试试看的态度,患者于2013年10月11日来我院检查治疗。检查:面色少华,倦怠流涎,失眠纳少,肢体麻木,表情呆滞,喜静恶动,短气懒言,舌淡苔薄,脉细缓。CT 检查示脑回变平,脑沟、脑裂增宽,脑室扩大,确诊为脑萎缩。
服用本实施例所得一种防治脑萎缩的益智健脑片剂,服用方法:每天三次,每次4-6片,温水送服,30天一个疗程。用药两个疗程后,患者面色红润、精神状态恢复正常,思路清晰;又用药两个疗程,患者走路基本恢复正常,思维能力提高,叮嘱坚持用药,保持愉悦心情。随访至今,患者情况稳定,无任何副反应。
实施例5 一种防治脑萎缩的益智健脑制剂,由下列原料药制备而成,均为重量份(40g/份):人参12.5份;山土瓜9.5份;三消草11份;水苏10份;远志11.5份;石花8.5份;益智仁12份;大枣14.5份;牛奶浆根11份;菊花13份;牛尾参11.5份;天水蚁草11.5份;白僵蚕8份;女贞子11.5份。
一种防治脑萎缩的益智健脑丸剂的制备方法是:
(1)取石花于黄酒中(石花与黄酒的质量比为1:0.20)浸泡15分钟,取出,文火加热炒干,研末,备用;白僵蚕置于瓦片上,炭火略炒至微黄色,取出放凉,研末备用;
(2)取人参切薄片和大枣一同置于药锅中,加冷水浸泡60分钟,然后盖盖,大火加热煮沸,转小火煎煮37分钟,过滤,滤液继续文火慢煎至原体积的1/4,放凉备用;
(3)将益智仁、女贞子和远志混合,粉碎成细粉,置于密闭容器中,加5.0倍量的乙醇于室温下浸泡4天,期间每天搅拌3次,待浸泡结束后,经三层面纱布过滤,滤液回收乙醇,减压浓缩至65℃相对密度为1.20的清膏,真空干燥,得干膏粉,备用;
(4)将山土瓜、三消草、水苏、牛奶浆根、菊花、牛尾参和天水蚁草置于中药干燥剂机中充分干燥,然后置于粉碎机中粉碎成细粉,备用;
(5)将步骤(1)、(3)和(4)处理后的原料药粉混合,过130目筛,加入到步骤(2)所得药液中,加入其它辅料(辅料为质量分数为9%的糖细粉和质量分数为3.5%的玉米淀粉),机械搅拌,混合均匀,加工成梧桐子大小的丸剂,即得。
本发明所得丸剂的服用方法是:每天三次,每次8-12粒,温水送服,30天一个疗程。
本发明所用主要中药原料的药理如下:
人参:基原:为五加科植物人参的根。性味:甘微苦,温。归经:入脾、肺经。功能主治:大补元气,固脱生津,安神。治劳伤虚损,食少,倦怠,反胃吐食,大便滑泄,虚咳喘促,自汗暴脱,惊悸,健忘,眩晕头痛,阳痿,尿频,消渴,妇女崩漏,小儿慢惊,及久虚不复,一切气血津液不足之证。
山土瓜:基原:旋花科番薯属植物山土瓜,以块根入药。性味:甘、淡,平。功能主治:健脾消积,利湿。用于小儿疳积,乳汁缺乏,肝炎,白带;外用治烧烫伤。
三消草:基原:为豆科植物白车轴草的全草。化学成份:全草含多种三萜皂甙,有车轴草皂甙Ⅰ、Ⅱ、Ⅲ、Ⅳ、Ⅴ的甲酯,β-D-吡喃葡萄糖醛酸基大豆皂醇B甲酯,大豆皂甙Ⅰ甲酯,大豆皂甙Ⅱ甲酯及赤豆皂甙Ⅱ甲酯等。全草、根、种子均含异黄酮,已知的有刺芒柄花素7-(C〃C-对羟基苯甲酸)-O-β-D-葡萄糖甙。叶含胡萝卜素和抗坏血酸,葡萄糖,果糖,D-肌酸甲醚,a,β-甲基葡萄糖甙,亚麻苦甙,氰甙,甘油酸。性味:味微甘;性平。归经:心;脾经。功能主治:清热;凉血;宁心。主癫病;痔疮出血;硬结肿快。
水苏:基原:为唇形科植物水苏、华水苏或毛水苏的全草或根。性味:味辛;性凉。归经:归肺;胃经。功能主治:清热解毒;止咳利咽;止血消肿。主感冒;痧症;肺痿;肺痈;头风目眩;咽痛;失间;吐血;咯血;衄血;崩漏;痢疾;淋证;跌打肿痛。
远志:基原:本品为远志科植物远志或卵叶远志的干燥根。化学成份:根含皂甙,水解后可分得两种皂甙元结晶,远志皂甙元A和远志皂甙元B。近又从本植物和同属美远志的根中分离出一种皂甙细叶远志素,即2β,27-二羟基-23-羧基齐墩果酸的3-β-葡萄糖甙。另含远志醇、N-乙酰氨基葡萄糖、生物碱细叶远志定碱、脂肪油、树脂等。性味:苦、辛,温。归经:归心、肾、肺经。功效:安神益智,祛痰,消肿。主治:用于心肾不交引起的失眠多梦、健忘惊悸、神志恍惚,咳痰不爽,疮疡肿毒,乳房肿痛。
石花:基原:为梅衣科植物石梅衣的地衣体。化学成份:地衣体含有藻纹苔酸。药理作用:黑茶渍素对鱼有毒。牛皮叶所含之酸性成分,味苦而有强烈的收敛性。性味:甘;性平。归经:肝;肾经。功能主治:补肾益肾;明目;止血,利湿解毒。。主视物模糊;腰膝疼痛;吐血;崩漏黄疸,疮癣。
益智仁:基原:为姜科植物益智的果实。性味:辛,温。归经:入脾,肾经。功能主治:温脾,暖肾,固气,涩精。治冷气腹痛,中寒吐泻,多唾,遗精,小便余沥,夜多小便。
大枣:基原:为鼠李科植物枣的成熟果实。化学成份:含大枣皂甙Ⅰ、Ⅱ、ⅢⅠ,Ⅱ,Ⅲ)、酸枣仁皂甙B、光千金藤碱、葡萄糖、果糖、蔗糖、环磷腺苷、环磷乌苷等。性味:甘,温。归经:入脾、胃经。功能主治:补脾和胃,益气生津,调营卫,解药毒。治胃虚食少,脾弱便溏,气血津液不足,营卫不和,心悸怔忡。妇人赃躁。
牛奶浆根:基原:为桑科植物天仙果的根。性味:甘;辛;性温。归经:肺;脾;肾经。功能主治:益气健脾;活血通络;祛风除湿。主劳倦乏力;食少;乳汁不下;脾虚白带;脱肛;月经不调;头风疼痛;跌打损伤;风湿性关节痛。
菊花:基原:为菊科植物菊的头状花序。性味:甘苦,凉。归经:入肺、肝经。功能主治:疏风,清热,明目,解毒。治头痛,眩晕,目赤,心胸烦热,疔疮,肿毒。
牛尾参:基原:为薯蓣科植物毛胶薯蓣的块茎。性味:甘;微辛;平。归经:脾;肺;肾经。功能主治:健脾去湿;补肺益肾。主脾虚食少;泄泻;肾虚遗精;消渴;肺劳咳嗽;跌打损伤。
天水蚁草:基原:为菊科植物秋鼠曲草的全草。性味:甘苦,平。归经:《闽东本草》:“入肺、肝二经。” 功能主治:疏风清热;解毒;利湿。主感冒;咳嗽;泄泻;痢疾;风湿痛;疮疡;瘰疬。
白僵蚕:又名僵蚕、天虫、白僵虫,为蚕蛾科蚕属动物家蚕蛾的幼虫感染白僵菌而僵死的全虫。药性:本品略呈圆柱形,多弯曲皱缩,表面灰黄色,质硬而脆,易折断,味辛、咸,性平。成分:白僵蚕含蛋白质、草氨酸,并含赖氨酸,亮氨酸,天冬氨酸等17种氨基酸。根据现代药理研究发现,该药具有祛风止痉、化痰散结、解毒利咽、抗惊厥、降血糖的功效,用于中风,偏正头痛,咽喉肿痛,风疹等。
女贞子:基原:为木犀科女贞属植物女贞的果实。成分:果实含三萜类:齐墩果酸,乙酰齐墩果酸,熊果酸,乙酰熊果酸;酚苷类:对羟基苯乙醇,3,4-二羟基苯乙醇,女贞子苷,橄榄苦苷,女贞果苷,女贞酸,女贞苷酸等。药性:甘、苦,凉。归肝、肾经。功能主治:补肝肾,强腰膝。治阴虚内热,头晕,目花,耳鸣,腰膝酸软,须发早白。滋补肝肾,明目乌发。用于眩晕耳鸣,腰膝酸软、须发早白、目暗不明。宜忌:脾胃虚寒泄泻及阳虚者慎服。
试验例1 本发明所得一种防治脑萎缩的益智健脑制剂(实施例5)的临床应用:
1、资料和方法
1.1 一般资料
筛选2011年10月-2014年3月我院收治的确诊为脑萎缩患者共300例,年龄在55-77岁,其中男性153例,女性147例,所有患者符合脑萎缩的诊断标准和中医辨证标准。
1.2 症状表现
(1)临床表现为记忆力减退,情绪不稳,思维能力减退,注意力不能集中,严重时发展为痴呆,终至智力丧失为其临床特征。
(2)辅助检查:CT 检查示脑回变平,脑沟、脑裂增宽,脑室扩大;MRI 检查亦可发现脑萎缩。
1.3 治疗方法
所有患者随机分为实验组和对照组,两组患者在性别、年龄、病程等方面,经统计学处理差异无显著性意义(P>0.05),具有可比性。其中实验组服用本发明所得药物,服用方法:每天三次,每次8-12粒,温水送服,30天一个疗程。对照组服用其它药品(如奥拉西坦、脑灵素片、脑活素等常规药品)。共观察治疗四个疗程。
1.4 疗效判定标准
临床治愈:临床症状和体征全部消失,能恢复一般社会活动,CT 扫描示脑萎缩状态改善。
显效:临床症状和体征部分消失或明显改善,行为活动基本恢复正常,CT 扫描示脑萎缩状态稳定或有改善。
好转:临床症状和体征有所缓解,但反应迟钝、智力障碍仍存在,CT 扫描示脑萎缩状态稳定。
无效:临床症状和体征无改善,甚至继续发展,CT 扫描示脑萎缩加重。
有效率=(临床治愈例+显效例+好转例)/总观察病例×100%。
1.5 治疗结果
两组患者的治疗结果如表1所示。
表1:实验组和对照组的治疗结果比较
治疗效果:实验组临床治愈139例(69.5%),显效33例(16.5%),好转24例(12%),无效4例(2%),总有效率98%。实验组治疗效果明显优于对照组。
本发明选择人参、山土瓜、三消草、水苏、远志、石花、益智仁、大枣和牛奶浆根等共14味主要原料药制备而成。方中,人参大补元气,固脱生津,安神;三消草清热,凉血,宁心;水苏清热解毒;远志安神益智,祛痰,消肿;石花补肾益肾,明目,利湿解毒;益智仁温脾,暖肾,固气;大枣补脾和胃,益气生津,调营卫,解药毒;牛奶浆根益气健脾,活血通络;天水蚁草疏风清热,解毒,利湿;女贞子补肝肾,强腰膝。诸药合用,加强活血化瘀、健脑通窍,益智安神之功。治疗四个疗程后,实验组总有效率为98%,而对照组仅为78%。
应当指出的是,具体实施方式只是本发明比较有代表性的例子,显然本发明的技术方案不限于上述实施例,还可以有很多变形。本领域的普通技术人员,以本发明所明确公开的或根据文件的书面描述毫无异议的得到的,均应认为是本专利所要保护的范围。
Claims (10)
1.一种防治脑萎缩的益智健脑制剂,其特征在于,由下列原料药制备而成,均为重量份:人参10-15;山土瓜7-12;三消草9-13;水苏6-14;远志8-15;石花7-10;益智仁9-15;大枣11-18;牛奶浆根8-14;菊花10-16;牛尾参7-16;天水蚁草9-14;白僵蚕6-10;女贞子10-13。
2.如权利要求1所述的一种防治脑萎缩的益智健脑制剂,其特征在于,由下列原料药制备而成,均为重量份:人参11.5-13.5;山土瓜9-10;三消草10-12;水苏8-12;远志10-13;石花8-9;益智仁11-13;大枣13-16;牛奶浆根10-12;菊花12-14;牛尾参10-13;天水蚁草10.5-12.5;白僵蚕7-9;女贞子11-12。
3.如权利要求1所述的一种防治脑萎缩的益智健脑制剂,其特征在于,由下列原料药制备而成,均为重量份:人参12.5;山土瓜9.5;三消草11;水苏10;远志11.5;石花8.5;益智仁12;大枣14.5;牛奶浆根11;菊花13;牛尾参11.5;天水蚁草11.5;白僵蚕8;女贞子11.5。
4.如权利要求1所述的一种防治脑萎缩的益智健脑制剂,其特征在于,将其制成药学上可接受的丸剂,制备方法如下:
(1)取石花于黄酒中浸泡12-18分钟(优选浸泡15分钟),取出,文火加热炒干,研末,备用;白僵蚕置于瓦片上,炭火略炒至微黄色,取出放凉,研末备用;
(2)取人参切薄片和大枣一同置于药锅中,加冷水浸泡50-70分钟(优选加冷水浸泡60分钟),然后盖盖,大火加热煮沸,转小火煎煮28-46分钟(优选转小火煎煮37分钟),过滤,滤液继续文火慢煎至原体积的1/4,放凉备用;
(3)将益智仁、女贞子和远志混合,粉碎成细粉,置于密闭容器中,加3.5-6.5倍量的乙醇于室温下浸泡3-5天(优选加5.0倍量的乙醇于室温下浸泡4天),期间每天搅拌,待浸泡结束后,经三层面纱布过滤,滤液回收乙醇,减压浓缩至65℃相对密度为1.18-1.22的清膏,真空干燥,得干膏粉,备用;
(4)将山土瓜、三消草、水苏、牛奶浆根、菊花、牛尾参和天水蚁草置于中药干燥剂机中充分干燥,然后置于粉碎机中粉碎成细粉,备用;
(5)将步骤(1)、(3)和(4)处理后的原料药粉混合,过115-145目筛(优选过130目筛),加入到步骤(2)所得药液中,加入其它辅料,机械搅拌,混合均匀,加工成梧桐子大小的丸剂,即得。
5.根据权利要求4所述的一种防治脑萎缩的益智健脑丸剂的制备方法,其特征在于,步骤(1)中石花与黄酒的质量比为1:0.15-0.25(优选的石花与黄酒的质量比为1:0.18-0.22,更加优选的石花与黄酒的质量比为1:0.20)。
6.根据权利要求4所述的一种防治脑萎缩的益智健脑丸剂的制备方法,其特征在于,步骤(3)中每天搅拌1-5次(优选的每天搅拌2-4次,更加优选的每天搅拌3次)。
7.根据权利要求4所述的一种防治脑萎缩的益智健脑丸剂的制备方法,其特征在于,步骤(5)中所述辅料为质量分数为9%的糖细粉和质量分数为3.5%的玉米淀粉。
8.如权利要求1所述的一种防治脑萎缩的益智健脑制剂,其特征在于,将其制成药学上可接受的胶囊剂,制备方法如下:
(1)取益智仁、女贞子、白僵蚕、菊花和石花置于密闭容器中,加22%-40%的姜汁拌匀(优选加30%的姜汁拌匀),闷8-14分钟(优选闷11分钟),取出,文火加热炒干,置于研钵中,研成细粉,备用;
(2)取三消草、水苏、大枣和天水蚁草置于药锅中,加清水没过药面,文火加热煎煮两次,第一次煎煮18-30分钟(优选第一次煎煮24分钟),第二次煎煮10-20分钟(优选第二次煎煮15分钟),合并两次煎液,过滤,滤液减压浓缩成稠膏,备用;
(3)取人参切成薄片,同山土瓜、远志、牛奶浆根和牛尾参一同粉碎成细粉,置于中药提取器中,以5-7倍量的55%的乙醇为溶剂(优选以6倍量的55%的乙醇为溶剂),加热回流提取24-40分钟(优选加热回流提取32分钟),收集提取液,过滤,回收乙醇,减压浓缩至60℃相对密度为1.22-1.25的稠膏,备用;
(4)将步骤(2)和(3)所得稠膏混合,加入步骤(1)所得药粉,搅拌使混合均匀,干燥,制粒,整粒,过六号筛,装入胶囊壳,即得。
9.如权利要求1所述的一种防治脑萎缩的益智健脑制剂,其特征在于,将其制成药学上可接受的汤剂,制备方法如下:
(1)取益智仁、白僵蚕、女贞子、远志和牛奶浆根于48-62℃干燥1-2小时(优选于55℃干燥1.5小时),趁热粉碎成细粉,将混合细粉平铺于渗漉筒内,以60%-80%的乙醇为溶剂(优选以70%的乙醇为溶剂),按照渗漉法收集渗漉液,待渗漉液的量为混合药粉量的16-20倍(优选渗漉液的量为混合药粉量的18倍)时,停止渗漉,过滤,回收乙醇,减压浓缩成稠膏,喷雾干燥得干膏粉,放凉,研细,备用;
(2)取人参切薄片,加清水文火慢煎1-2小时(优选加清水文火慢煎1.5小时),过滤,滤液备用;
(3)取山土瓜、三消草、水苏、石花、大枣、菊花、牛尾参和天水蚁草置于砂锅内,加4-7倍量的清水浸泡2-4小时(优选加5.5倍量的清水浸泡3小时),然后大火加热煮沸3-7分钟(优选大火加热煮沸5分钟),转小火煎煮45-65分钟(优选小火煎煮55分钟),过滤,滤液备用;
(4)将步骤(2)和步骤(3)所得滤液混合,减压浓缩至原体积的1/3,然后加入步骤(1)处理后的干膏粉,搅拌均匀,灭菌封装,即得。
10.如权利要求1所述的一种防治脑萎缩的益智健脑制剂,其特征在于,将其制成药学上可接受的片剂,制备方法如下:
(1)取人参切薄片,大枣去核、切薄片,一同置于干燥机中,低温烘干,研磨成细粉,备用;
(2)将益智仁、女贞子置于15%的黄酒中,拌匀,闷10-20分钟(优选闷15分钟),取出,置于炒至容器中,与白僵蚕一同翻炒至微黄色,取出放凉,研成细粉,备用;
(3)将除步骤(1)和(2)以外的原料药置于热风干燥机中,于72-80℃干燥34-50分钟(优选于76℃干燥42分钟),再于45-55℃干燥1-2小时(优选于50℃干燥1.5小时),取出,置于粉碎机中粉碎成细粉,备用;
(4)将步骤(1)-(3)处理后的原料药粉混合,加入糊精细粉和硬脂酸镁,搅拌均匀,过65-95目筛(优选过80目筛),置于压片机中压成片剂,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510503756.2A CN104998174A (zh) | 2015-08-18 | 2015-08-18 | 一种防治脑萎缩的益智健脑制剂及制法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510503756.2A CN104998174A (zh) | 2015-08-18 | 2015-08-18 | 一种防治脑萎缩的益智健脑制剂及制法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104998174A true CN104998174A (zh) | 2015-10-28 |
Family
ID=54371210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510503756.2A Pending CN104998174A (zh) | 2015-08-18 | 2015-08-18 | 一种防治脑萎缩的益智健脑制剂及制法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104998174A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111743992A (zh) * | 2020-06-23 | 2020-10-09 | 西安岐奥丰医疗发展有限公司 | 参茸健脑胶囊及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1201691A (zh) * | 1998-06-23 | 1998-12-16 | 杨克勤 | 治疗脑萎缩疾病的药物及其制备方法 |
WO2013063536A1 (en) * | 2011-10-27 | 2013-05-02 | Acceleron Pharma, Inc. | Actriib binding agents and uses thereof |
-
2015
- 2015-08-18 CN CN201510503756.2A patent/CN104998174A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1201691A (zh) * | 1998-06-23 | 1998-12-16 | 杨克勤 | 治疗脑萎缩疾病的药物及其制备方法 |
WO2013063536A1 (en) * | 2011-10-27 | 2013-05-02 | Acceleron Pharma, Inc. | Actriib binding agents and uses thereof |
Non-Patent Citations (1)
Title |
---|
周德生: "《中老年食疗养生入门》", 30 September 2012, 上海世纪出版股份有限公司 上海科学技术出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111743992A (zh) * | 2020-06-23 | 2020-10-09 | 西安岐奥丰医疗发展有限公司 | 参茸健脑胶囊及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102048933B (zh) | 一种治疗小儿腹泻的中药组合物及其制备方法 | |
CN104435775A (zh) | 一种中药保健酒及其制备方法 | |
CN103520572B (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN104398986A (zh) | 一种安神补脑的淫羊藿口服液及其制备方法 | |
CN104904964A (zh) | 一种降糖降脂的罗布麻叶保健茶及其制备方法 | |
CN102755596B (zh) | 一种治疗痰湿型乳腺增生的中药及制备方法 | |
CN104305205B (zh) | 一种提高免疫力的菟丝子口服液及其制备方法 | |
CN105031517A (zh) | 一种降三高的铁皮石斛保健茶及其制备方法 | |
CN103301413A (zh) | 一种治疗高血脂合并高血糖症的中药组合物 | |
CN104958607A (zh) | 一种治疗妇女更年期灼口综合征的中药组合物及方法 | |
CN104398790A (zh) | 一种防治心悸失眠、神经衰弱的罗布麻叶口服液及其制备方法 | |
CN103735835A (zh) | 一种治疗少白头的中药制剂及其制备方法 | |
CN104905267A (zh) | 一种决明子降血脂保健口服液及其制备方法 | |
CN104206595A (zh) | 一种降脂降糖的地骨皮保健茶及其制备方法 | |
CN106173605A (zh) | 一种包含葛根和石斛的降血糖保健组合物 | |
CN104274754A (zh) | 一种治疗小儿遗尿的中药组合物及其制备方法 | |
CN101732685A (zh) | 一种针灸用的皮肤表面浸润中药制剂 | |
CN103749819A (zh) | 一种降糖降脂的山茱萸保健茶及其制备方法 | |
CN104888158A (zh) | 一种提高免疫力的罗布麻叶口服液及其制备方法 | |
CN104644967A (zh) | 一种治疗i型糖尿病的药物组合物及其应用 | |
CN103301341A (zh) | 一种治疗缺血性脑中风的中药组合物 | |
CN104998174A (zh) | 一种防治脑萎缩的益智健脑制剂及制法 | |
CN105535587A (zh) | 一种治疗心肾不交型心悸失眠的中药制剂及其制备方法 | |
CN105343502A (zh) | 一种可提高免疫力的保健口服液 | |
CN106177476A (zh) | 一种包含石斛和陈皮的降血糖保健组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 536000 the Guangxi Zhuang Autonomous Region City, Haicheng District, Guangdong Road, No. 79, and district, building 3, 1-202 Applicant after: Li Rongzhen Address before: Hualong Road, Licheng District, Shandong city of Ji'nan Province, No. 6 250000 Applicant before: Li Rongzhen |
|
COR | Change of bibliographic data | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151028 |
|
RJ01 | Rejection of invention patent application after publication |